Jump to Header Jump to Main Content Jump to Footer

Ph Ib RMC-6291 in Comb w/ RMC-6236 in Pts w/ Adv KRASG12C Mutated Solid Tumors

Zhaohui Ann Arter


A Study On:

  • Anus
  • Bones and Joints
  • Brain and Nervous System
  • Breast
  • Cervix
  • Colon
  • Corpus Uteri
  • Esophagus
  • Eye and Orbit
  • Ill-Defined Sites
  • Kaposi's Sarcoma
  • Kidney
  • Larynx
  • Lip, Oral Cavity and Pharynx
  • Liver
  • Lung
  • Melanoma, Skin
  • Other Digestive Organ
  • Other Endocrine System
  • Other Female Genital
  • Other Male Genital
  • Other Respiratory and Intrathoracic Organs
  • Other Skin
  • Other Urinary
  • Ovary
  • Pancreas
  • Prostate
  • Rectum
  • Small Intestine
  • Soft Tissue
  • Stomach
  • Thyroid
  • Unknown Sites
  • Urinary Bladder

Status:

  • Open

Eligibility

Male and Female Adults

Official Title

Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C-Mutated Solid Tumors

Details

This study is to evaluate the safety, tolerability, and PK profiles of RMC-6291 and RMC-6236 in adults with KRAS G12C-mutated solid tumors.


Eligibility

You can join if...

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study

Inclusion Criteria:

18 years of age

Histology: pathologically, KRAS G12C-mutated, documented advanced or metastatic solid tumors not amendable to curative therapy

Part 1. Dose Escalation: solid tumors, previously treated

Part 2. Dose Expansion:

i.Non-small cell lung cancer (NSCLC), previously treated with immunotherapy, chemotherapy, and KRAS G12C (OFF) inhibitors,

ii. NSCLC, previously treated with immunotherapy and chemotherapy, naïve to KRAS G12C (OFF) inhibitors,

iii. NSCLC, previously treated with immunotherapy, chemotherapy, with untreated, asymptomatic central nervous system (CNS) metastases <2 cm in size

iv. Solid tumors, previously treated, naïve to KRAS G12C (OFF) inhibitors.

ECOG performance status 0 or 1

Adequate organ function

Exclusion Criteria:

i. Primary central nervous system (CNS) tumors

ii. Active brain metastases

iii. Known impairment of gastrointestinal function that would alter the absorption

iv. Major surgical procedures within 28 days or non-study related minor procedures within 7 days of treatment

Get in touch with our study team